Type 2 diabetes is a risk factor for dementia and Alzheimer’s. Novo Nordisk, which makes Ozempic and Wegovy, is running two ...

While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) drug, and is the active agent in Ozempic and its weight-loss cousin, Wegovy.

This week, Novo Nordisk, the Copenhagen, Denmark based pharmaceutical company, asked the US Food and Drug Administration (FDA ...

Novo Nordisk is continuing its crusade against compounded versions of its blockbuster weight loss drugs by petitioning the ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

In an observational study, Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among ...

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according ...

Nearly 7 million Americans 65 and older are living with Alzheimer’s disease, which gradually destroys memory and thinking ...

West Pharmaceutical Services raised its annual profit forecast on Thursday, after beating Wall Street estimates for quarterly revenue and profit, banking on rising demand for cartridges and syringes ...

The full-year cost of care for U.S. patients with obesity two years after starting on Novo Nordisk’s Wegovy or similar GLP-1 ...

Drugs such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro are approved to treat diabetes patients and have proven more ...